TY - JOUR
T1 - Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer
AU - Weiser, Martin R.
AU - Hsu, Meier
AU - Bauer, Philip S.
AU - Chapman, William C.
AU - González, Iván A.
AU - Chatterjee, Deyali
AU - Lingam, Deepak
AU - Mutch, Matthew G.
AU - Keshinro, Ajaratu
AU - Shia, Jinru
AU - Vakiani, Efsevia
AU - Konishi, Tsuyoshi
AU - Shimada, Yoshifumi
AU - Stadler, Zsofia
AU - Segal, Neil H.
AU - Cercek, Andrea
AU - Saltz, Leonard
AU - Yaeger, Rona
AU - Varghese, Anna
AU - Widmar, Maria
AU - Wei, Iris H.
AU - Pappou, Emmanouil P.
AU - Smith, J. Joshua
AU - Nash, Garrett
AU - Paty, Philip
AU - Garcia-Aguilar, Julio
AU - Gonen, Mithat
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2021/3/10
Y1 - 2021/3/10
N2 - PURPOSEClinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third-generation clinical calculator was built to predict recurrence following resection of stage I-III colon cancer.METHODSProspectively collected data from 1,095 patients who underwent colectomy between 2007 and 2014 at Memorial Sloan Kettering Cancer Center were used to develop a clinical calculator. Discrimination was measured with concordance index, and variability in individual predictions was assessed with calibration curves. The clinical calculator was externally validated with a patient cohort from Washington University's Siteman Cancer Center in St Louis.RESULTSThe clinical calculator incorporated six variables: microsatellite genomic phenotype; AJCC T category; number of tumor-involved lymph nodes; presence of high-risk pathologic features such as venous, lymphatic, or perineural invasion; presence of tumor-infiltrating lymphocytes; and use of adjuvant chemotherapy. The concordance index was 0.792 (95% CI, 0.749 to 0.837) for the clinical calculator, compared with 0.708 (95% CI, 0.671 to 0.745) and 0.757 (0.715 to 0.799) for the staging schemes of the AJCC manual's 5th and 8th editions, respectively. External validation confirmed robust performance, with a concordance index of 0.738 (95% CI, 0.703 to 0.811) and calibration plots of predicted probability and observed events approaching a 45° diagonal.CONCLUSIONThis third-generation clinical calculator for predicting cancer recurrence following curative colectomy successfully incorporates microsatellite genomic phenotype and the presence of tumor-infiltrating lymphocytes, resulting in improved discrimination and predictive accuracy. This exemplifies an evolution of a clinical calculator to maintain relevance by incorporating emerging variables as they become validated and accepted in the oncologic community.
AB - PURPOSEClinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third-generation clinical calculator was built to predict recurrence following resection of stage I-III colon cancer.METHODSProspectively collected data from 1,095 patients who underwent colectomy between 2007 and 2014 at Memorial Sloan Kettering Cancer Center were used to develop a clinical calculator. Discrimination was measured with concordance index, and variability in individual predictions was assessed with calibration curves. The clinical calculator was externally validated with a patient cohort from Washington University's Siteman Cancer Center in St Louis.RESULTSThe clinical calculator incorporated six variables: microsatellite genomic phenotype; AJCC T category; number of tumor-involved lymph nodes; presence of high-risk pathologic features such as venous, lymphatic, or perineural invasion; presence of tumor-infiltrating lymphocytes; and use of adjuvant chemotherapy. The concordance index was 0.792 (95% CI, 0.749 to 0.837) for the clinical calculator, compared with 0.708 (95% CI, 0.671 to 0.745) and 0.757 (0.715 to 0.799) for the staging schemes of the AJCC manual's 5th and 8th editions, respectively. External validation confirmed robust performance, with a concordance index of 0.738 (95% CI, 0.703 to 0.811) and calibration plots of predicted probability and observed events approaching a 45° diagonal.CONCLUSIONThis third-generation clinical calculator for predicting cancer recurrence following curative colectomy successfully incorporates microsatellite genomic phenotype and the presence of tumor-infiltrating lymphocytes, resulting in improved discrimination and predictive accuracy. This exemplifies an evolution of a clinical calculator to maintain relevance by incorporating emerging variables as they become validated and accepted in the oncologic community.
UR - http://www.scopus.com/inward/record.url?scp=85102658077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102658077&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.02553
DO - 10.1200/JCO.20.02553
M3 - Article
C2 - 33439688
AN - SCOPUS:85102658077
SN - 0732-183X
VL - 39
SP - 911
EP - 919
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -